Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
about
Recent developments in drug discovery for leishmaniasis and human African trypanosomiasisOne Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual ScreeningStructure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the LeishmaniasesHigh-resolution structures ofTrypanosoma bruceipteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug targetStructure of recombinantLeishmania donovanipteridine reductase reveals a disordered active siteThe crystal structure of Leishmania major N5,N10-methylenetetrahydrofolate dehydrogenase/cyclohydrolase and assessment of a potential drug targetStructure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking InvestigationsMetabolic signatures of triatomine vectors of Trypanosoma cruzi unveiled by metabolomicsTranscriptome Remodeling in Trypanosoma cruzi and Human Cells during Intracellular InfectionTrypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in miceIn silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis.TRAPP webserver: predicting protein binding site flexibility and detecting transient binding pockets.Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1.LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of LeishmaniaLmABCB3, an atypical mitochondrial ABC transporter essential for Leishmania major virulence, acts in heme and cytosolic iron/sulfur clusters biogenesis.Methylene tetrahydrofolate dehydrogenase/cyclohydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major.Ursolic Acid, a Natural Pentacylcic Triterpene from Ochrosia elliptica and Its Role in The Management of Certain Neglected Tropical Diseases.Folate metabolic pathways in LeishmaniaGenomic organization of leishmania species.Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoxygenase that can possess anti-inflammatory properties.In-silico analyses of sesquiterpene-related compounds on selected Leishmania enzyme-based targets.In-silico Leishmania target selectivity of antiparasitic terpenoids.Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis.Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents.Application of a simple quantum chemical approach to ligand fragment scoring for Trypanosoma brucei pteridine reductase 1 inhibition.Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery.Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard Leishmania.Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information.Genetically Validated Drug Targets in Leishmania; Current Knowledge and Future Prospects.Silver-catalyzed decarboxylative acylation of quinoxalin-2(1H)-ones with α-oxo-carboxylic acids.Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors.Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis
P2860
Q27011766-8514443F-7E8E-4874-B3C5-E49DF227FB79Q27655956-BD57C940-1EC3-4B43-9681-634E18DF85FDQ27658197-0B776D8D-2A1E-4446-8C1F-8A8130EED9EEQ27666140-BDF0716E-D839-4131-BF95-30BEAE55AB3EQ27666482-2990AC5C-EBE3-4DD0-82B5-79D40DA31572Q27675760-05629FC4-A637-4DF9-93DD-E238E741924EQ27684633-7F1999BF-6B02-4EA0-8473-30041D8A2782Q28066944-4ED9558B-FCB1-468E-9614-F063A98B241CQ28534750-5DC76BDE-AA65-43BA-BE86-1C57F24F041EQ28551174-A8BF44CD-C63B-42FF-86E9-11A627A4F3D2Q34044853-12D5C896-957D-4B95-A946-02D36FC7D326Q34528982-C23C3407-EF7C-4481-90FE-EE57B08E2D80Q34555623-078D858C-A34A-4D8C-B0CB-96F42E3CD072Q34619406-31135A82-24D4-4EB7-9A21-F5862FB736ECQ34702464-93E9CEB1-80D9-4DA1-A640-1C4626703650Q36428337-A14BC875-2675-43E9-8815-B4242540E662Q37217438-F2019BEA-2C9F-47F1-958C-021772313C15Q37394710-A561406D-5E33-4A70-B936-D269326973C3Q37948934-0DE09877-86F5-448A-BA9F-2B95FB74CCBDQ37985972-6B202281-39B8-4982-96F3-F0B8599439C6Q38958116-D4DA7541-EC66-4F53-9F80-160511C6B073Q39200387-7854D72D-CD40-4331-AD41-FFCF5C4E0322Q39318097-D47F961E-13BF-4AC1-AA43-E4B0E643E2D1Q39328997-9F1830CE-3E41-49BA-9B91-56464BAE6540Q39386461-EAABAD26-6443-49E2-BE3C-24E864E6D35EQ41365032-7B518260-14F9-4F8F-96D8-F6B546C7C1C4Q41515537-801C9FCC-AA20-4CEF-B8DD-E8443F843C5DQ42163449-57D1027B-A89A-4D72-A343-F68FF2965A74Q42732972-4A3BAC2E-5C85-4B77-B4FF-DED35F3E0E22Q43046133-4BB91E71-1960-480D-95E3-F5D145BBB8DCQ45213048-8DAFED5A-E28D-43CB-8D10-5DBC4E719BA4Q47702679-836D70B1-DC7C-46B8-9F5F-AA171C19FCD2Q50078850-E6EC4DCD-805A-4925-8C9B-90DF721E13C5Q51102354-B7FFE0E6-2B10-4C28-943B-6A5AD7B97AC2Q51541343-11518551-A477-40F5-B5A4-8CC229EC6ADDQ57190987-3198FFF7-771C-402D-8CFE-A925E7B8E9AA
P2860
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@ast
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@en
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@nl
type
label
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@ast
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@en
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@nl
prefLabel
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@ast
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@en
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@nl
P2093
P2860
P50
P3181
P356
P1476
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
@en
P2093
Antonio Cavazzuti
Federica Gibellini
Giuseppe Paglietti
Karen McLuskey
Mario Loriga
Paola Corona
Sandra Piras
Sergio Allecca
P2860
P304
P3181
P356
10.1073/PNAS.0704384105
P407
P577
2008-02-01T00:00:00Z